

Remarks

Claims 1-41 were pending. Claims 38-41 are canceled.

In response to the restriction requirement, Applicants elect the invention of Group I, Claims 1-37. With respect to the species election requirements, Applicants elect the following species.

Species of purine or pyrimidine analog: (b) a nitrogenous base. Applicants note that the generic claims of the invention are directed to a method wherein a purine or pyrimidine analog is provided to a cell in the presence of particular enzymes. Among the group of purine or pyrimidine analogs are included various uracil analogs. Such analogs can be provided to a cell in the form of a free nitrogenous base (Claim 31), or as a nucleoside (Claim 32), which term refers to a nitrogenous base further comprising a deoxyribose or ribose sugar moiety. The generic term "nitrogenous base" encompasses uracil analogs, provided in the form of a free base. The generic term "nucleoside" encompasses uracil analogs, provided in the form of a base bound to a deoxyribose or ribose sugar moiety. Therefore, Claims 1-30 and 33-37 are generic to species b, Claim 32 is withdrawn.

Species of tags: (d) a small molecule binding partner. Applicants submit that Claim 7, which is directed to the use of biotin, is properly dependent on Claim 6 (small molecule), because biotin is a species with the genus of small molecule binding partners. The generic term "small molecule binding partner" encompasses biotin. Claims 10 and 11 are further dependent on Claim 6, because they add the further limitation that the small molecule binding partner is bound to its partner, where the partner may additionally be conjugated to an insoluble substrate, and thus these claims are within the genus defined by (d). Therefore, Claims 1-5 and 23-37 are generic with respect to species of tags. Claims 8-9 and 20-21 are withdrawn. Claims 6-7, 10-19 specifically read on the elected species.

Species of methods for processing separated RNA: (k) RNA is amplified. Claims 1-11, 18-21 and 23-37 are generic. Claim 13 reads on the elected species.

Species of promoters: (q) constitutively active. Claims 1-22 and 28-37 are generic, Claim 23 reads on the elected species, Claims 24-27 are withdrawn.

Species of vectors: (v) a replicable vector. Claims 1-27 and 31-37 are generic, Claim 28 reads on the elected species, Claims 29-30 are withdrawn.


CONCLUSION

Applicants submit that all of the claims are now in condition for allowance, which action is requested. If the Examiner finds that a Telephone Conference would expedite the prosecution of this application, he is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number STAN-304.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: August 30, 2006

By: 
Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231